AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24193112 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 605
Study 24193112 — intervention group
Group type: COMPARATOR
Intervention: Control group (EM)
Number of subjects: 605
Study 21410100 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional pain control infusion pump
Number of subjects: 24
Study 21410100 — intervention group
Group type: COMPARATOR
Intervention: Placebo pain control infusion pump
Number of subjects: 24
Study 19617576 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated factor IX levels
Number of subjects: 1489
Study 19617576 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated factor XI levels
Number of subjects: 1489
Study 19617576 — intervention group
Group type: COMPARATOR
Intervention: Factor XII deficiency
Number of subjects: 1489
Study 16765272 — intervention group
Group type: EXPERIMENTAL
Intervention: Single data extraction
Number of subjects: 0
Study 16765272 — intervention group
Group type: COMPARATOR
Intervention: Double data extraction
Number of subjects: 0
Study 15581425 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg b.d. for 7 days or until discharge
Number of subjects: 50
Study 15581425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 11718218 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher lesional viral load at study entry
Number of subjects: 40
Study 11718218 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-6
Number of subjects: 40
Study 11718218 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-11
Number of subjects: 40
Study 11718218 — intervention group
Group type: COMPARATOR
Intervention: HPV-16
Number of subjects: 40
Study 11718218 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-61
Number of subjects: 40
Study 11718218 — intervention group
Group type: COMPARATOR
Intervention: Demographic and epidemiological data, or risk factors
Number of subjects: 40
Study 8511635 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group with situational involvement (decision reviewed by peers)
Number of subjects: 48
Study 8511635 — intervention group
Group type: COMPARATOR
Intervention: Control group without situational involvement
Number of subjects: 48
Study 3498392 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg X kg‐1 propofol
Number of subjects: 16
Study 3498392 — intervention group
Group type: COMPARATOR
Intervention: 1.5 mg X kg‐1 ketamine
Number of subjects: 16
Study 323835 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine (Disadine D.P.)
Number of subjects: 101
Study 323835 — intervention group
Group type: COMPARATOR
Intervention: Control (no povidone-iodine)
Number of subjects: 101
Study 29489726 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-leg Roman chair hold
Number of subjects: 12
Study 29489726 — intervention group
Group type: COMPARATOR
Intervention: Nordic hamstring curl
Number of subjects: 12
Study 28199996 — intervention group
Group type: EXPERIMENTAL
Intervention: First-trimester placental growth factor (PlGF) measurements at 8+0 to 10+6 weeks and 11+0 to 14+0 weeks of gestation.
Number of subjects: 814
Study 28199996 — intervention group
Group type: EXPERIMENTAL
Intervention: First-trimester placental growth factor (PlGF) measurements.
Number of subjects: 814
Study 28199996 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ‐PlGF in pregnancies complicated by PE.
Number of subjects: 814
Study 26302249 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 0
Study 26302249 — intervention group
Group type: COMPARATOR
Intervention: Cognitive psychoeducation (CPE)
Number of subjects: 0
Study 26302249 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 22780582 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% CO₂ inhalation
Number of subjects: 0
Study 22780582 — intervention group
Group type: COMPARATOR
Intervention: Medical air (placebo)
Number of subjects: 0
Study 21195255 — intervention group
Group type: EXPERIMENTAL
Intervention: Damon Q
Number of subjects: 0
Study 21195255 — intervention group
Group type: EXPERIMENTAL
Intervention: In‐Ovation R
Number of subjects: 0
Study 21195255 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed
Number of subjects: 0
Study 18617176 — intervention group
Group type: COMPARATOR
Intervention: Controls (7 patients)
Number of subjects: 17
Study 18617176 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CAD (5 patients)
Number of subjects: 17
Study 18617176 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with AnCAD (5 patients)
Number of subjects: 17
Study 17364151 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair (LG)
Number of subjects: 170
Study 17364151 — intervention group
Group type: COMPARATOR
Intervention: Anterior-open repair (OG)
Number of subjects: 170
Study 15550798 — intervention group
Group type: EXPERIMENTAL
Intervention: QI-Meds
Number of subjects: 1299
Study 15550798 — intervention group
Group type: EXPERIMENTAL
Intervention: QI-Therapy
Number of subjects: 1299
Study 15550798 — intervention group
Group type: COMPARATOR
Intervention: Quality Improvement (QI) programs
Number of subjects: 1299
Study 11152830 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR stent
Number of subjects: 849
Study 11152830 — intervention group
Group type: COMPARATOR
Intervention: PS stent
Number of subjects: 849
Study 9451886 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc-99m-methyl-diphosphate (MDP) bone scans
Number of subjects: 15
Study 9451886 — intervention group
Group type: EXPERIMENTAL
Intervention: Sestamibi (MIBI) bone scans
Number of subjects: 15
Study 9451886 — intervention group
Group type: EXPERIMENTAL
Intervention: MIBI bone scans post-chemotherapy
Number of subjects: 15
Study 8179134 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg human corticotropin releasing hormone
Number of subjects: 42
Study 8179134 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg human corticotropin releasing hormone
Number of subjects: 42
Study 8179134 — intervention group
Group type: COMPARATOR
Intervention: Control group (no human corticotropin releasing hormone)
Number of subjects: 42
Study 3332509 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 tablets of 'Fansimef' (500 mg mefloquine base, 1000 mg sulfadoxine, 50 mg pyrimethamine)
Number of subjects: 60
Study 3332509 — intervention group
Group type: COMPARATOR
Intervention: 3 tablets of 'Fansimef' (500 mg mefloquine base, 1000 mg sulfadoxine, 50 mg pyrimethamine)
Number of subjects: 60
Study 29999517 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative immunonutrition (IMPACT®)
Number of subjects: 276
Study 29999517 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative immunonutrition (IMPACT®)
Number of subjects: 276
Study 29999517 — intervention group
Group type: COMPARATOR
Intervention: Perioperative standard nutrition
Number of subjects: 276
Study 29999517 — intervention group
Group type: COMPARATOR
Intervention: Preoperative standard nutrition
Number of subjects: 276
Study 28800722 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 121
Study 28800722 — intervention group
Group type: COMPARATOR
Intervention: Propofol-remifentanil
Number of subjects: 121
Study 26361810 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium phosphate containing desensitizer paste (TAP)
Number of subjects: 35
Study 26361810 — intervention group
Group type: COMPARATOR
Intervention: Water as placebo (PLA)
Number of subjects: 35
Study 24028716 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4(+) T cells from IRH patients
Number of subjects: 40
Study 24028716 — intervention group
Group type: COMPARATOR
Intervention: CD4(+) T cells from aplastic anemia patients
Number of subjects: 40
Study 21145578 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 μg dose of 2009 H1N1 vaccine
Number of subjects: 390
Study 21145578 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg dose of 2009 H1N1 vaccine
Number of subjects: 390
Study 21145578 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 μg dose of 2009 H1N1 vaccine in patients older than 60 years with severe asthma
Number of subjects: 390
Study 21145578 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg dose of 2009 H1N1 vaccine in patients older than 60 years with severe asthma
Number of subjects: 390
Study 21145578 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 15 μg and 30 μg doses of 2009 H1N1 vaccine
Number of subjects: 390
Study 21145578 — intervention group
Group type: EXPERIMENTAL
Intervention: 2009 H1N1 vaccine
Number of subjects: 390
Study 18509570 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based support (n = 12)
Number of subjects: 35
Study 18509570 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual occupation-based support (n = 11)
Number of subjects: 35
Study 18509570 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group and individual support intervention (n = 12)
Number of subjects: 35
Study 18509570 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 35
Study 17115871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.2 mg/kg
Number of subjects: 18
Study 17115871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.4 mg/kg
Number of subjects: 18
Study 17115871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 18
Study 17115871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 14985213 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate (40 g soy protein, 118 mg isoflavones)
Number of subjects: 50
Study 14985213 — intervention group
Group type: COMPARATOR
Intervention: Casein placebo
Number of subjects: 50
Study 11687731 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-inhibitor trandolapril (4 mg)
Number of subjects: 0
Study 11687731 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dihydropyridinic Ca2+ channel blocker verapamil (240 mg)
Number of subjects: 0
Study 11687731 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of trandolapril (2 mg) and verapamil (180 mg)
Number of subjects: 0
Study 11687731 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0
Study 9405587 — intervention group
Group type: EXPERIMENTAL
Intervention: 850 microg/d synthetic folic acid
Number of subjects: 24
Study 9405587 — intervention group
Group type: COMPARATOR
Intervention: 450 microg/d synthetic folic acid
Number of subjects: 24
Study 12959316 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic tranylcypromine (20 mg of the sulphate)
Number of subjects: 6
Study 12959316 — intervention group
Group type: EXPERIMENTAL
Intervention: Single enantiomers of tranylcypromine (10 mg of the sulphate)
Number of subjects: 6
Study 12959316 — intervention group
Group type: COMPARATOR
Intervention: Both enantiomers
Number of subjects: 6
Study 2872878 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin
Number of subjects: 261
Study 2872878 — intervention group
Group type: COMPARATOR
Intervention: Tinidazole
Number of subjects: 261
Study 31957104 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke volume-based fluid resuscitation protocol
Number of subjects: 64
Study 31957104 — intervention group
Group type: COMPARATOR
Intervention: Control (no protocol)
Number of subjects: 64
Study 30462706 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular fixation
Number of subjects: 35
Study 30462706 — intervention group
Group type: COMPARATOR
Intervention: Dominant eye fixation
Number of subjects: 35
Study 30462706 — intervention group
Group type: COMPARATOR
Intervention: Non-dominant eye fixation
Number of subjects: 35
Study 28712216 — intervention group
Group type: EXPERIMENTAL
Intervention: Clamping trial before removal (Group A)
Number of subjects: 180
Study 28712216 — intervention group
Group type: COMPARATOR
Intervention: Immediate removal without clamping trial (Group B)
Number of subjects: 180
Study 24739993 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 165
Study 24739993 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo tablets
Number of subjects: 165
Study 24739993 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised dietary program (offered to randomized participants)
Number of subjects: 165
Study 24739993 — intervention group
Group type: COMPARATOR
Intervention: Blood specimens from controls without IIH
Number of subjects: 165
Study 23418301 — intervention group
Group type: EXPERIMENTAL
Intervention: Action‐observation training (AOT)
Number of subjects: 52
Study 23418301 — intervention group
Group type: COMPARATOR
Intervention: Standard Toy Observation Training (TOT)
Number of subjects: 52
Study 20185897 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (n = 18)
Number of subjects: 38
Study 20185897 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (n = 15)
Number of subjects: 38
Study 20185897 — intervention group
Group type: COMPARATOR
Intervention: Autogenic training (control group, n = 5)
Number of subjects: 38
Study 18079431 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative parecoxib 40 mg
Number of subjects: 320
Study 18079431 — intervention group
Group type: COMPARATOR
Intervention: Postoperative parecoxib
Number of subjects: 320
Study 18079431 — intervention group
Group type: COMPARATOR
Intervention: Single preoperative parecoxib dose
Number of subjects: 320
Study 16563131 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine
Number of subjects: 60
Study 16563131 — intervention group
Group type: COMPARATOR
Intervention: Oxybutynin
Number of subjects: 60
Study 12584282 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa at doses of 0.45 and 0.75 microg/kg/week
Number of subjects: 122
Study 12584282 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa continued for up to 52 weeks
Number of subjects: 122
Study 12584282 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 122
Study 11041909 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (12.5, 25, or 50 mg combined)
Number of subjects: 5435
Study 11041909 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs (ibuprofen, diclofenac, or nabumetone combined)
Number of subjects: 5435
Study 8640968 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 392
Study 8640968 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 392
Study 8640968 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 392
Study 8640968 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 392
Study 1377305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 1377305 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (morning dosage) 20 mg
Number of subjects: 34
Study 1377305 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (evening dosage) 20 mg
Number of subjects: 34
Study 6730873 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 25 mg
Number of subjects: 100
Study 6730873 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride 0.9% (Control)
Number of subjects: 100
Study 6730873 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 2.5 mg
Number of subjects: 100
Study 6730873 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 25 micrograms
Number of subjects: 100
Study 31183923 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen screening and digital rectal examination
Number of subjects: 0
Study 31183923 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29486797 — intervention group
Group type: EXPERIMENTAL
Intervention: BTH1677 (4 mg/kg IV weekly) + bevacizumab (15 mg/kg IV Q3W) + carboplatin (6 mg/mL/min Calvert formula Q3W) + paclitaxel (200 mg/m2 Q3W)
Number of subjects: 92
Study 29486797 — intervention group
Group type: COMPARATOR
Intervention: Control (bevacizumab + carboplatin + paclitaxel as above)
Number of subjects: 92
Study 29486797 — intervention group
Group type: EXPERIMENTAL
Intervention: BTH1677 arm
Number of subjects: 92
Study 29486797 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 92
Study 29486797 — intervention group
Group type: EXPERIMENTAL
Intervention: BTH1677/bevacizumab/carboplatin/paclitaxel
Number of subjects: 92
Study 29486797 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 92
Study 27622613 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard pin configuration
Number of subjects: 138
Study 27622613 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorgan's method
Number of subjects: 138
Study 24699939 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg every 2 weeks (q2w)
Number of subjects: 187
Study 24699939 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg q2w
Number of subjects: 187
Study 24699939 — intervention group
Group type: COMPARATOR
Intervention: Sirukumab (all doses)
Number of subjects: 187
Study 21316934 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol supplementation (4 g per day via 2 plant sterol-enriched yogurt mini drinks)
Number of subjects: 108
Study 21316934 — intervention group
Group type: COMPARATOR
Intervention: Control (yogurt beverage without phytosterols)
Number of subjects: 108
Study 19769596 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage (CHO) for 12 days (Study 1)
Number of subjects: 50
Study 19769596 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage (PRO) for 12 days (Study 1)
Number of subjects: 50
Study 19769596 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage (CHO) for 21 days (Study 2)
Number of subjects: 50
Study 19769596 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage (PRO) for 21 days (Study 2)
Number of subjects: 50
Study 17563146 — intervention group
Group type: EXPERIMENTAL
Intervention: BI‐A (2 sessions with the adolescent only)
Number of subjects: 79
Study 17563146 — intervention group
Group type: EXPERIMENTAL
Intervention: BI‐AP (2 sessions with the adolescent and 1 with the parent)
Number of subjects: 79
Study 17563146 — intervention group
Group type: COMPARATOR
Intervention: CON (assessment‐only control condition)
Number of subjects: 79
Study 17563146 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 79
Study 15591331 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (Group P)
Number of subjects: 42
Study 15591331 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane/nitrous oxide (Group S)
Number of subjects: 42
Study 12391385 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg/day of folic acid
Number of subjects: 95
Study 12391385 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg/day of folic acid
Number of subjects: 95
Study 12391385 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg/day of folic acid
Number of subjects: 95
Study 12391385 — intervention group
Group type: COMPARATOR
Intervention: 0 microg/day of folic acid (placebo)
Number of subjects: 95
Study 9920100 — intervention group
Group type: EXPERIMENTAL
Intervention: GH replacement therapy
Number of subjects: 14
Study 9920100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7484282 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium tablets 1 g/night
Number of subjects: 168
Study 7484282 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk powder containing 1 g of calcium
Number of subjects: 168
Study 7484282 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium tablets 1 g/night and exercise regimen
Number of subjects: 168
Study 7484282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 2301454 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose combined drug therapy (propranolol and chlorthalidone) with an educational program on hypertension, dietary and exercise modification.
Number of subjects: 95
Study 2301454 — intervention group
Group type: COMPARATOR
Intervention: High-comparison group (control) receiving no specific intervention.
Number of subjects: 95
Study 7028089 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate
Number of subjects: 0
Study 7028089 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone phosphate
Number of subjects: 0
Study 7028089 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone phosphate
Number of subjects: 0
Study 7028089 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 0
Study 7028089 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone
Number of subjects: 0
Study 30761486 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA amendment
Number of subjects: 0
Study 30761486 — intervention group
Group type: EXPERIMENTAL
Intervention: BC amendment
Number of subjects: 0
Study 30761486 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 28655538 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal collagen crosslinking (CXL)
Number of subjects: 179
Study 28655538 — intervention group
Group type: COMPARATOR
Intervention: Sham control (riboflavin alone without removal of the epithelium)
Number of subjects: 179
Study 26826113 — intervention group
Group type: EXPERIMENTAL
Intervention: Physically active academic lessons (2 consecutive school years, 22 weeks per year, 3 times a week, 20-30 min per lesson)
Number of subjects: 499
Study 26826113 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 499
Study 24972949 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional trivalent split virion vaccine (TIIV)
Number of subjects: 60
Study 24972949 — intervention group
Group type: EXPERIMENTAL
Intervention: Virosome-adjuvanted trivalent inactivated influenza vaccine (VATIIV)
Number of subjects: 60
Study 22653877 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐AMT
Number of subjects: 61
Study 22653877 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐AMT
Number of subjects: 61
Study 22653877 — intervention group
Group type: EXPERIMENTAL
Intervention: L/D‐AMT
Number of subjects: 61
Study 22653877 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro uptake by the human proton‐coupled folate transporter (PCFT)
Number of subjects: 61
Study 19289172 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg caffeine
Number of subjects: 27
Study 19289172 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/kg caffeine
Number of subjects: 27
Study 19289172 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg caffeine
Number of subjects: 27